ENHERTU (trastuzumab deruxtecan) is a targeted therapy that can cause a serious lung condition, often referred to as interstitial lung disease (ILD) or pneumonitis. This is a significant potential side effect that requires careful monitoring and prompt medical attention.
Understanding the Lung Condition
This serious lung condition involves inflammation of the lung tissue, which can impair lung function. While Enhertu is designed to target cancer cells, it can, in some cases, affect healthy lung tissue, leading to this adverse reaction. The severity can range from mild to life-threatening.
Key Symptoms to Watch For
It is crucial for patients receiving Enhertu to be aware of the potential signs of this lung condition. Early detection and intervention are vital.
Possible symptoms include:
- Cough: A new or worsening cough.
- Fever: An unexplained elevation in body temperature.
- Shortness of Breath: Difficulty breathing or feeling breathless, especially with activity.
- Any Other Change in Breathing: This could include wheezing, chest discomfort, or a feeling of tightness in the chest.
What to Do If Symptoms Develop
If you are receiving Enhertu treatment and develop any of the symptoms mentioned above, it is imperative to talk with your doctor right away. Do not wait for symptoms to worsen. Your healthcare provider will evaluate your condition, which may include imaging tests of your lungs.
Potential Actions:
- Monitoring: Your doctor will closely monitor your respiratory symptoms and overall lung health.
- Treatment Adjustments: If a serious lung condition is diagnosed, your doctor will likely have you stop Enhertu treatment. This discontinuation is often necessary to prevent further progression of the lung damage.
- Supportive Care: Depending on the severity, supportive care, such as oxygen therapy or medications to reduce inflammation, may be administered.
Being vigilant about these symptoms and communicating promptly with your healthcare team is essential for managing this potential serious side effect of Enhertu.
